Eledon Pharmaceuticals Submits IND To FDA For Registrational Tegoprubart Study In Islet Cell Transplantation For Type 1 Diabetes; Reaffirms Q4 2026 Initiation Of Phase 3 LEGACY Kidney Transplant Trial
Share
Why It Matters
Eledon Pharmaceuticals got permission to test a new medicine for diabetes patients who receive cell transplants. This shows the company is moving forward with its plans, which tells us management is confident in their drug.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.